Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

December 12, 2023

Novel Drug Has Survival Benefit in Stem Cell Transplant-Related GVHD

Author(s):

Gina Mauro
Conference|American Society of Hematology Annual Meeting

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.

GVHD image

The novel cell therapy Orca-Q demonstrated early signals of relapse-free and overall survival benefits, in addition to an acceptable side effect profile, in patients undergoing haploidentical (a half-matched donor) stem cell transplantation without posttransplant cyclophosphamide, as shown in findings from a phase 1 trial.

Results from this trial were presented during the 2023 ASH Annual Meeting.

Results showed that both the graft-versus-host disease (GVHD) relapse-free survival (the time after treatment when a patient with cancer survives without symptoms or signs of the disease) rate and overall survival (the time from the start of treatment that a patient with cancer is alive) rate at one year was 82% with Orca-Q. This is in comparison to historical data with conventional posttransplant cyclophosphamide (a drug used to treat cancer by damaging the cell’s DNA to destroy cancer cells, although it may lower a patient’s immune response) for haploidentical stem cell transplantation, with recent one-year GVHD relapse-free survival rates of 46%.

“These findings show promising safety and efficacy outcomes using Orca-Q cell therapy for haploidentical transplant,” said Samer A. Srour, lead study author and assistant professor in the department of stem cell transplantation at The University of Texas MD Anderson Cancer Center in Houston, in an oral presentation during the meeting. “No safety signals in this haploidentical setting were identified.”

Standard allogeneic stem cell transplantation can be a curative approach for patients across many high-risk hematologic cancers, although access to this therapy was previously limited to those who have a fully matched donor. The introduction of posttransplant cyclophosphamide as prophylaxis (attempting to prevent a disease) for GVHD increased the utility of haploidentical donors; however, it has also increased relapse rates and toxicity issues such as cytokine release syndrome (a condition after some types of immunotherapy, during which cytokines are rapidly released into the blood), delayed engraftment and T-cell reconstitution, mucositis (inflammation of the lining of the digestive system), infections, heart-related events and non-relapse mortality, Srour added.

However, GVHD relapse-free survival rates in this patient population remain low. Through allograft optimization, Orca-Q may improve haploidentical stem cell transplantation.

The trial enrolled patients aged 18 to 65 years with the following high-risk hematologic cancers: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), very high– or high-risk myelodysplastic syndrome or myelofibrosis.

The main goals of the study were to assess side effects that may limit the doses administered to patients and primary graft failure.

Off the 33 patients enrolled onto the study, the median age is 43 years. Their primary disease was ALL (30.3%), AML (63.3%) or chronic myeloid leukemia (6.1%). Additionally, patients had high-/very high­–risk disease (18%) or intermediate-risk disease (79%).

Patients’ disease status at time of transplant encompassed those who achieved their first complete remission (the disappearance of all signs of cancer from treatment; 73%), second complete remission (24%) and CML accelerated phase (when cells grow faster and lead to symptoms like weight loss, fatigue, fever and enlarged spleen; 3%).

Rapid engraftment with Orca-Q was observed in the patients. The median engraftment time with neutrophils (a type of white blood cell) was 12 days and 15.5 days with platelets (pieces of cells that helps blood clot). Two patients experienced secondary graft failure, and mild to moderate cytokine release syndrome occurred in three patients.

Additional data showed a low incidence of moderate (nine patients) and severe or worse (15 patients) infections. There were five events (15%) of acute moderate to life-threatening GVHD and one event of severe acute GVHD. At a median follow-up of 375 days, no patients have developed moderate to severe chronic GVHD. This in comparison to historical cohorts with posttransplant cyclophosphamide, which show one-year chronic GVHD rates of 24% to 33%.

The phase 1 trial is continuing to enroll patients across the United States. Srour stated that there are plans to increase the age criteria to 75 years and provide less-intensive conditioning therapy.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Related Content
Advertisement
ctDNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma: © vitanovski - stock.adobe.com.
August 20th 2025

DNA Test Outperforms PET/CT Scans When Detecting Lymphoma

Spencer Feldman
cancer horizons logo: a white microphone on a navy blue background
August 20th 2025

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Image of two people with text.
August 20th 2025

Patients and Caregivers Aim to Raise Funds for Myeloma Research

Ryan Scott
CURE Cancer Horizons podcast logo
August 20th 2025

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
August 20th 2025

Finishing Cancer Treatment Didn’t Bring the Relief You’d Expect

Karen Cohn
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 20th 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
Related Content
Advertisement
ctDNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma: © vitanovski - stock.adobe.com.
August 20th 2025

DNA Test Outperforms PET/CT Scans When Detecting Lymphoma

Spencer Feldman
cancer horizons logo: a white microphone on a navy blue background
August 20th 2025

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Image of two people with text.
August 20th 2025

Patients and Caregivers Aim to Raise Funds for Myeloma Research

Ryan Scott
CURE Cancer Horizons podcast logo
August 20th 2025

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
August 20th 2025

Finishing Cancer Treatment Didn’t Bring the Relief You’d Expect

Karen Cohn
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 20th 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.